NCT04676503View on ClinicalTrials.gov

Vaginal and Rectal Colonization of Lactobacillus Crispatus NTCVAG04 Following Oral Administration in Patients With History of Vaginitis/Vaginosis

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

May 27, 2020

Study Completion Date

July 21, 2020

Conditions
VaginitisVaginosis
Interventions
DIETARY_SUPPLEMENT

BIOVAGINIL

Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 μg.

Trial Locations (1)

53100

Azienda Ospedaliera Universitaria di Siena - Unità Operativa Semplice Ginecologia Endocrinologica Centro Sterilità di Coppia, Siena

All Listed Sponsors
lead

NTC srl

INDUSTRY

NCT04676503 - Vaginal and Rectal Colonization of Lactobacillus Crispatus NTCVAG04 Following Oral Administration in Patients With History of Vaginitis/Vaginosis | Biotech Hunter | Biotech Hunter